Myfortic Magasýruþolin tafla 180 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

myfortic magasýruþolin tafla 180 mg

novartis healthcare a/s - mycophenolatum natríum - magasýruþolin tafla - 180 mg

Myfortic Magasýruþolin tafla 360 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

myfortic magasýruþolin tafla 360 mg

novartis healthcare a/s - mycophenolatum natríum - magasýruþolin tafla - 360 mg

Qinlock 유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

qinlock

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinal stromal tumors - Æxlishemjandi lyf - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.